Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Journal of Neuroinflammation
Published in: Journal of Neuroinflammation 1/2005

Open Access 01-12-2005 | Research

Anti-inflammatory therapy by ibudilast, a phosphodiesterase inhibitor, in demyelination of twitcher, a genetic demyelination model

Authors: Kuriko Kagitani-Shimono, Ikuko Mohri, Yasushi Fujitani, Kinuko Suzuki, Keiichi Ozono, Yoshihiro Urade, Masako Taniike

Published in: Journal of Neuroinflammation | Issue 1/2005

Login to get access

Abstract

Background

Twitcher mouse (twi/twi) is an authentic murine model of Krabbe's disease. Accumulation of psychosine, resulting in apoptosis of oligodendrocytes and subsequent demyelination, is a cardinal event to the pathogenesis of this disease. Moreover, recruitment of inflammatory cells plays a significant role in the pathological process in the twi/twi central and peripheral nervous systems. In this study, we investigated the 1) the relationship between tumor necrosis factor-α (TNFα), pro-inflammatory cytokine, and the progression of this disease and 2) effect of the anti-inflammatory therapy by ibudilast, a phosphodiesterase inhibitor.

Methods

We quantified the expression level of TNFα and TNF-receptor mRNA in twi/twi using semi-quantitative RT-PCR. The relationship between TNFα expression, apoptosis of oligodendrocytes and demyelination was studied with immunohistochemistry and TUNEL method. We then treated twi/twi with a daily intraperitoneal injection of ibudilast (10 mg/kg), which suppress TNFα production in the brain.

Results

We found that TNFα-immunoreactive microglia/macrophages appeared in the twi/twi brain and that the mRNA levels of TNFα and TNF-receptor 1 was increased with the progression of demyelination. The distribution profile of TNFα-immunoreactive microglia/macrophages overlapped that of TUNEL-positive oligodendrocytes in the twi/twi brain. When twi/twi was treated with ibudilast from PND30, the number of oligodendrocytes undergoing apoptosis was markedly reduced and demyelination was milder. Obvious improvement of clinical symptom was noted in two of five. The failure of constant clinical improvement by ibudilast may result from hepatotoxicity and/or the inhibition of proliferation of NG2-positive oligodendrocyte precursors.

Conclusion

We conclude that anti-inflammatory therapy by a phosphodiesterase inhibitor can be considered as a novel alternative therapy for Krabbe's disease.
Appendix
Available only for authorised users
Literature
1.
Duchen LW, Eicher EM, Jacobs JM, Scaravilli F, Teixeira F: Hereditary leucodystrophy in the mouse: the new mutant twitcher. Brain. 1980, 103: 695-710.CrossRefPubMed
2.
Kobayashi T, Yamanaka T, Jacobs JM, Teixeira F, Suzuki K: The Twitcher mouse: an enzymatically authentic model of human globoid cell leukodystrophy (Krabbe disease). Brain Res. 1980, 202: 479-483. 10.1016/0006-8993(80)90159-6.CrossRefPubMed
3.
Suzuki K, Suzuki K: The twitcher mouse. A model of human globoid cell leukodystrophy (krabbe's disease). Am J Pathol. 1983, 111: 394-397.PubMedCentralPubMed
4.
Taniike M, Suzuki K: Spacio-temporal progression of demyelination in twitcher mouse: with clinico-pathological correlation. Acta Neuropathol (Berl). 1994, 88: 228-236.CrossRef
5.
Suzuki K, Taniike M: Murine model of genetic demyelinating disease: the twitcher mouse. Microsc Res Tech. 1995, 32: 204-214. 10.1002/jemt.1070320304.CrossRefPubMed
6.
Suzuki K, Hoogerbrugge PM, Poorthuis BJ, Bekkum DW, Suzuki K: The twitcher mouse. Central nervous system pathology after bone marrow transplantation. Lab Invest. 1988, 58: 302-309.PubMed
7.
Ohno M, Komiyama A, Martin PM, Suzuki K: MHC class II antigen expression and T-cell infiltration in the demyelinating CNS and PNS of the twitcher mouse. Brain Res. 1993, 625: 186-196. 10.1016/0006-8993(93)91058-Z.CrossRefPubMed
8.
Matsushima GK, Taniike M, Glimcher LH, Grusby MJ, Frelinger JA, Suzuki K, Ting JP: Absence of MHC class II molecules reduces CNS demyelination, microglial/macrophage infiltration, and twitching in murine globoid cell leukodystrophy. Cell. 1994, 78: 645-656. 10.1016/0092-8674(94)90529-0.CrossRefPubMed
9.
Taniike M, Marcus JR, Nishigaki T, Fujita N, Popko B, Suzuki K, Suzuki K: Suppressed UDP-galactose: ceramide galactosyltransferase and myelin protein mRNA in twitcher mouse brain. J Neurosci Res. 1998, 51: 536-540. 10.1002/(SICI)1097-4547(19980215)51:4<536::AID-JNR13>3.0.CO;2-1.CrossRefPubMed
10.
Wu YP, McMahon EJ, Matsuda J, Suzuki K, Matsushima GK, Suzuki K: Expression of immune-related molecules is downregulated in twitcher mice following bone marrow transplantation. J Neuropathol Exp Neurol. 2001, 60: 1062-1074.PubMed
11.
LeVine SM, Brown DC: IL-6 and TNFalpha expression in brains of twitcher, quaking and normal mice. J Neuroimmunol. 1997, 73: 47-56. 10.1016/S0165-5728(96)00166-X.CrossRefPubMed
12.
Taniike M, Mohri I, Eguchi N, Irikura D, Urade Y, Okada S, Suzuki K: An apoptotic depletion of oligodendrocytes in the twitcher, a murine model of globoid cell leukodystrophy. J Neuropathol Exp Neurol. 1999, 58: 644-653.CrossRefPubMed
13.
Akassoglou K, Bauer J, Kassiotis G, Pasparakis M, Lassmann H, Kollias G, Probert L: Oligodendrocyte apoptosis and primary demyelination induced by local TNF/p55TNF receptor signaling in the central nervous system of transgenic mice: models for multiple sclerosis with primary oligodendrogliopathy. Am J Pathol. 1998, 153: 801-813.PubMedCentralCrossRefPubMed
14.
Taguchi I, Oka K, Kitamura K, Sugiura M, Oku A, Matsumoto M: Protection by a cyclic AMP-specific phosphodiesterase inhibitor, rolipram, and dibutyryl cyclic AMP against Propionibacterium acnes and lipopolysaccharide-induced mouse hepatitis. Inflamm Res. 1999, 48: 380-385. 10.1007/s000110050475.CrossRefPubMed
15.
Suzumura A, Ito A, Yoshikawa M, Sawada M: Ibudilast suppresses TNFalpha production by glial cells functioning mainly as type III phosphodiesterase inhibitor in the CNS. Brain Res. 1999, 837: 203-212. 10.1016/S0006-8993(99)01666-2.CrossRefPubMed
16.
Fujimoto T, Sakoda S, Fujimura H, Yanagihara T: Ibudilast, a phosphodiesterase inhibitor, ameliorates experimental autoimmune encephalomyelitis in Dark August rats. J Neuroimmunol. 1999, 95: 35-42. 10.1016/S0165-5728(98)00251-3.CrossRefPubMed
17.
Sakai N, Inui K, Tatsumi N, Fukushima H, Nishigaki T, Taniike M, Nishimoto J, Tsukamoto H, Yanagihara I, Ozono K, Okada S: Molecular cloning and expression of cDNA for murine galactocerebrosidase and mutation analysis of the twitcher mouse, a model of Krabbe's disease. J Neurochem. 1995, 66: 1118-1124.CrossRef
18.
Loeffler J, Henke N, Hebart H, Schmidt D, Hagmeyer L, Schumacher U, Einsele H: Quantification of fungal DNA by using fluoresence energy transfer and the light cycler system. J Clin Microbiol. 2000, 38: 586-590.PubMedCentralPubMed
19.
Wang JY, Montone KT: A rapid simple in situ hybridization method for herpes simplex virus employing a synthetic biotin-labeled oligonucleotide probe: a comparison with immunohistochemical methods for HSV detection. J Clin Lab Anal. 1994, 8: 105-115.CrossRefPubMed
20.
Unger ER, Brigati DJ: Colorimetric in-situ hybridization in clinical virology: development of automated technology. Curr Top Microbiol Immunol. 1989, 143: 21-31.PubMed
21.
Selmaj KW, Raine CS: Tumor necrosis factor mediates myelin and oligodendrocyte damage in vitro. Ann Neurol. 1988, 23: 339-346. 10.1002/ana.410230405.CrossRefPubMed
22.
Zajicek JP, Wing M, Scolding NJ, Compston DA: Interactions between oligodendrocytes and microglia. A major role for complement and tumour necrosis factor in oligodendrocyte adherence and killing. Brain. 1992, 115: 1611-1631.CrossRefPubMed
23.
Probert L, Akassoglou K, Kassiotis G, Pasparakis M, Alexopoulou L, Kollias G: TNF-alpha transgenic and knockout models of CNS inflammation and degeneration. J Neuroimmunol. 1997, 72: 137-141. 10.1016/S0165-5728(96)00184-1.CrossRefPubMed
24.
Lannuzel A, Aubourg P, Tardieu M: Excessive production of tumour necrosis factor alpha by peripheral blood mononuclear cells in X-linked adrenoleukodystrophy. Eur J Paediatr Neurol. 1998, 2: 27-32. 10.1016/1090-3798(98)01002-7.CrossRefPubMed
25.
Hofman FM, Hinton DR, Johnson K, Merrill JE: Tumor necrosis factor identified in multiple sclerosis brain. J Exp Med. 1989, 170: 607-612. 10.1084/jem.170.2.607.CrossRefPubMed
26.
Taupin V, Renno T, Bourbonniere L, Peterson AC, Rodriguez M, Owens T: Increased severity of experimental autoimmune encephalomyelitis, chronic macrophage/microglial reactivity, and demyelination in transgenic mice producing tumor necrosis factor-alpha in the central nervous system. Eur J Immunol. 1997, 27: 905-913.CrossRefPubMed
27.
Bachmann R, Eugster HP, Frei K, Fontana A, Lassmann H: Impairment of TNF-receptor-1 signaling but not fas signaling diminishes T-cell apoptosis in myelin oligodendrocyte glycoprotein peptide-induced chronic demyelinating autoimmune encephalomyelitis in mice. Am J Pathol. 1999, 154: 1417-1422.PubMedCentralCrossRefPubMed
28.
Eugster HP, Frei K, Bachmann R, Bluethmann H, Lassmann H, Fontana A: Severity of symptoms and demyelination in MOG-induced EAE depends on TNFR1. Eur J Immunol. 1999, 29: 626-632. 10.1002/(SICI)1521-4141(199902)29:02<626::AID-IMMU626>3.3.CO;2-1.CrossRefPubMed
29.
Probert L, Eugster HP, Akassoglou K, Bauer J, Frei K, Lassmann H, Fontana A: TNFR1 signalling is critical for the development of demyelination and the limitation of T-cell responses during immune-mediated CNS disease. Brain. 2000, 123: 2005-2019. 10.1093/brain/123.10.2005.CrossRefPubMed
30.
Mizuno T, Butler D, Kurotani T, Komatsu Y, Kawanokuchi J, Kato H, Mitsuma N, Suzumura A: Neuroprotective role of phosphodiesterase inhibitor ibudilast on neuronal cell death induced by activated microglia. Neuropharmacology. 2004, 46: 404-411. 10.1016/j.neuropharm.2003.09.009.CrossRefPubMed
31.
Giri S, Jatana M, Rattan R, Won JS, Singh I, Singh AK: Galactosylsphingosine (psychosine)-induced expression of cytokine-mediated inducible nitric oxide synthases via AP-1 and C/EBP: implications for Krabbe disease. FASEB J. 2002, 16: 661-672. 10.1096/fj.01-0798com.CrossRefPubMed
32.
Baker D, Butler D, Scallon BJ, O'Neill JK, Turk JL, Feldmann M: Control of established experimental allergic encephalomyelitis by inhibition of tumor necrosis factor (TNF) activity within the central nervous system using monoclonal antibodies and TNF receptor-immunoglobulin fusion proteins. Eur J Immunol. 1994, 24: 2040-2048.CrossRefPubMed
33.
Selmaj KW, Raine CS: Experimental autoimmune encephalomyelitis: immunotherapy with anti-tumor necrosis factor antibodies and soluble tumor necrosis factor receptors. Neurology. 1995, 45: S44-S49.CrossRefPubMed
34.
Liu J, Marino MW, Wong G, Grail D, Dunn A, Bettadapura J, Slavin AJ, Old L, Bernard CC: TNF is a potent anti-inflammatory cytokine in autoimmune-mediated demyelination. Nat Med. 1998, 4: 78-83. 10.1038/nm0198-078.CrossRefPubMed
35.
TNF neutralization in MS: results of a randomized, placebo-controlled multicenter study. The Lenercept Multiple Sclerosis Study Group and The University of British Columbia MS/MRI Analysis Group. Neurology. 1999, 53: 457-465.
36.
Mohan N, Edwards ET, Cupps TR, Oliverio PJ, Sandberg G, Crayton H, Richert JR, Siegel JN: Demyelination occurring during anti-tumor necrosis factor alpha therapy for inflammatory arthritides. Arthritis Rheum. 2001, 44: 2862-2869. 10.1002/1529-0131(200112)44:12<2862::AID-ART474>3.0.CO;2-W.CrossRefPubMed
37.
Thomas CW, Weinshenker BG, Sandborn WJ: Demyelination during anti-tumor necrosis factor alpha therapy with infliximab for Crohn's disease. Inflamm Bowel Dis. 2004, 10: 28-31. 10.1097/00054725-200401000-00004.CrossRefPubMed
38.
Panitch HS: Early treatment trials with interferon beta in multiple sclerosis. Mult Scler. 1995, S17-21.
39.
Placebo-controlled multicentre randomised trial of interferon beta-1b in treatment of secondary progressive multiple sclerosis. European Study Group on interferon beta-1b in secondary progressive MS. Lancet. 1998, 352: 1491-1497. 10.1016/S0140-6736(98)10039-9.
40.
41.
Wolinsky JS: Copolymer 1: a most reasonable alternative therapy for early relapsing-remitting multiple sclerosis with mild disability. Neurology. 1995, 45: 1245-1247.CrossRefPubMed
42.
Weber MS, Starck M, Wagenpfeil S, Meinl E, Hohlfeld R, Farina C: Multiple sclerosis: glatiramer acetate inhibits monocyte reactivity in vitro and in vivo. Brain. 2004, 127: 1370-1378. 10.1093/brain/awh163.CrossRefPubMed
43.
Gayo A, Mozo L, Suarez A, Tunon A, Lahoz C, Gutierrez C: Interferon beta-1b treatment modulates TNFalpha and IFNgamma spontaneous gene expression in MS. Neurology. 1999, 52: 1764-1770.CrossRefPubMed
44.
Laske C, Oschmann P, Tofighi J, Kuehne SB, Diehl H, Bregenzer T, Kraus J, Bauer R, Chatzimanolis N, Kern A, Traupe H, Kaps M: Induction of sTNF-R1 and sTNF-R2 by interferon beta-1b in correlation with clinical and MRI activity. Acta Neurol Scand. 2001, 103: 105-113. 10.1034/j.1600-0404.2001.103002105.x.CrossRefPubMed
45.
Arnett HA, Mason J, Marino M, Suzuki K, Matsushima GK, Ting JP: TNF alpha promotes proliferation of oligodendrocyte progenitors and remyelination. Nature Neuroscience. 2001, 4: 1116-1122. 10.1038/nn738.CrossRefPubMed
46.
Hu WH, Johnson H, Shu HB: Activation of NF-kappaB by FADD, Casper, and caspase-8. J Biol Chem. 2000, 275: 10838-10844. 10.1074/jbc.275.15.10838.CrossRefPubMed
47.
Yeager AM, Brennan S, Tiffany C, Moser HW, Santos GW: Prolonged survival and remyelination after hematopoietic cell transplantation in the twitcher mouse. Science. 1984, 225: 1052-1054.CrossRefPubMed
48.
Biswas S, Pinson DM, Bronshteyn IG, LeVine SM: IL-6 deficiency allows for enhanced therapeutic value after bone marrow transplantation across a minor histocompatibility barrier in the twitcher (globoid cell leukodystrophy) mouse. J Neurosci Res. 2001, 15: 298-307. 10.1002/jnr.1154.CrossRef
49.
Metadata
Title
Anti-inflammatory therapy by ibudilast, a phosphodiesterase inhibitor, in demyelination of twitcher, a genetic demyelination model
Authors
Kuriko Kagitani-Shimono
Ikuko Mohri
Yasushi Fujitani
Kinuko Suzuki
Keiichi Ozono
Yoshihiro Urade
Masako Taniike
Publication date
01-12-2005
Publisher
BioMed Central
Published in
Journal of Neuroinflammation / Issue 1/2005
Electronic ISSN: 1742-2094
DOI
https://doi.org/10.1186/1742-2094-2-10

Other articles of this Issue 1/2005

Journal of Neuroinflammation 1/2005 Go to the issue

Research

Differential regulation of Aβ42-induced neuronal C1q synthesis and microglial activation

Research

Infiltrative microgliosis: activation and long-distance migration of subependymal microglia following periventricular insults

Research

Interleukin 1 receptor antagonist knockout mice show enhanced microglial activation and neuronal damage induced by intracerebroventricular infusion of human β-amyloid

Research

Early correlation of microglial activation with enhanced tumor necrosis factor-alpha and monocyte chemoattractant protein-1 expression specifically within the entorhinal cortex of triple transgenic Alzheimer's disease mice

Research

Signaling pathways mediating a selective induction of nitric oxide synthase II by tumor necrosis factor alpha in nerve growth factor-responsive cells

Research

Astrocyte production of the chemokine macrophage inflammatory protein-2 is inhibited by the spice principle curcumin at the level of gene transcription